Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
Clinical trial NCT07154082 · RECRUITING
Trial details
- NCT number
- NCT07154082
- Sponsor
- Wei Zhang
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-30
- Primary completion
- 2027-12-31
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.